Analysts Anticipate Chromadex Corp (NASDAQ:CDXC) to Post -$0.12 EPS
Analysts predict that Chromadex Corp (NASDAQ:CDXC) will post earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Chromadex’s earnings, with estimates ranging from ($0.12) to ($0.11). Chromadex posted earnings of ($0.16) per share during the same quarter last year, which would suggest a positive year over year growth rate of 25%. The firm is expected to report its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that Chromadex will report full-year earnings of ($0.50) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.47). For the next financial year, analysts forecast that the company will report earnings of ($0.09) per share, with EPS estimates ranging from ($0.24) to $0.09. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Chromadex.
Chromadex (NASDAQ:CDXC) last posted its earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The company had revenue of $11.10 million for the quarter, compared to the consensus estimate of $10.81 million. Chromadex had a negative return on equity of 136.15% and a negative net margin of 85.86%.
Shares of NASDAQ CDXC traded down $0.09 during midday trading on Tuesday, reaching $4.20. 131,143 shares of the company were exchanged, compared to its average volume of 207,091. The stock’s 50-day moving average price is $4.19 and its 200-day moving average price is $4.21. The stock has a market cap of $249.50 million, a P/E ratio of -6.89 and a beta of 1.40. Chromadex has a one year low of $2.79 and a one year high of $4.95. The company has a quick ratio of 1.11, a current ratio of 1.55 and a debt-to-equity ratio of 0.09.
Large investors have recently modified their holdings of the company. Granite Investment Partners LLC lifted its holdings in shares of Chromadex by 87.7% during the first quarter. Granite Investment Partners LLC now owns 167,689 shares of the company’s stock worth $702,000 after purchasing an additional 78,373 shares during the period. Tieton Capital Management LLC lifted its holdings in shares of Chromadex by 15.1% during the first quarter. Tieton Capital Management LLC now owns 1,257,890 shares of the company’s stock worth $5,271,000 after purchasing an additional 165,425 shares during the period. Spark Investment Management LLC acquired a new position in shares of Chromadex during the first quarter worth $78,000. BNP Paribas Arbitrage SA acquired a new position in shares of Chromadex during the first quarter worth $34,000. Finally, BlackRock Inc. lifted its holdings in shares of Chromadex by 15.4% during the second quarter. BlackRock Inc. now owns 2,238,654 shares of the company’s stock worth $10,410,000 after purchasing an additional 298,126 shares during the period. Institutional investors own 19.76% of the company’s stock.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Featured Article: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.